Latest Breaking News On - Ocelot bio - Page 1 : comparemela.com

Ocelot Bio Receives FDA Orphan Drug Designation for OCE-205 for the Treatment of Ascites

Ocelot Bio Receives FDA Orphan Drug Designation for OCE-205 for the Treatment of Ascites

Ocelot Bio, Inc., a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics to treat complications of end-stage liver disease (ESLD), today announced that the U.S. Food and Drug Administration (FDA) has granted.

Propulsion of Hepatorenal Syndrome Clinical Trial Pipeline as Novel and Extensive 3+ Therapies Likely to Enter in the Domain | DelveInsight

(Albany, United States) As per DelveInsight’s assessment, globally, the Hepatorenal Syndrome Pipeline constitutes 3+ key companies continuously working towards developing 3+ Hepatorenal Syndrome Pipeline treatment

Women in Science: Katherine Vega Stultz on Ocelot's plans and fostering her 'CEO sisterhood' at Bio International

Katherine Vega Stultz is the CEO and president of Ocelot Bio, a clinical-stage biotech company focused on the development of therapeutics to treat complications of end-stage liver disease.